CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Bob Olsson; Ronald Lautner; Ulf Andreasson; Annika Öhrfelt; Erik Portelius; Maria Bjerke; Mikko Hölttä; Christoffer Rosén; Caroline Olsson; Gabrielle Strobel; Elizabeth Wu; Kelly Dakin; Max Petzold; Kaj Blennow; Henrik Zetterberg

doi:10.1016/s1474-4422(16)00070-3

journal article Jun 01, 2016

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Bob Olsson Ronald Lautner Ulf Andreasson Annika Öhrfelt Erik Portelius Maria Bjerke Mikko Hölttä Christoffer Rosén Caroline Olsson Gabrielle Strobel Elizabeth Wu Kelly Dakin Max Petzold

Kaj Blennow Henrik Zetterberg

The Lancet Neurology Vol. 15 No. 7 pp. 673-684 · Elsevier BV

View at Publisher Save 10.1016/s1474-4422(16)00070-3

Topics

No keywords indexed for this article. Browse by subject →

References

34

[1]

Alzheimer's disease

Kaj Blennow, Mony J de Leon, Henrik Zetterberg

The Lancet 2006 10.1016/s0140-6736(06)69113-7

[2]

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway, Reisa Sperling, Nick C. Fox et al.

New England Journal of Medicine 2014 10.1056/nejmoa1304839

[3]

de Souza "CSF tau markers are correlated with hippocampal volume in Alzheimer's disease" Neurobiol Aging (2012) 10.1016/j.neurobiolaging.2011.02.022

[4]

Tapiola "Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain" Arch Neurol (2009) 10.1001/archneurol.2008.596

[5]

Hesse "Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke" Neurosci Lett (2001) 10.1016/s0304-3940(00)01697-9

[6]

Ost "Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury" Neurology (2006) 10.1212/01.wnl.0000242732.06714.0f

[7]

Buerger "CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease" Brain (2006) 10.1093/brain/awl269

[8]

Seppala "CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings" Neurology (2012) 10.1212/wnl.0b013e3182563bd0

[9]

Blennow "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease" Nat Rev Neurol (2010) 10.1038/nrneurol.2010.4

[10]

Schott "New criteria for Alzheimer's disease: which, when and why?" Brain (2015) 10.1093/brain/awv055

[11]

Sutphen "Progress update: fluid and imaging biomarkers in Alzheimer's disease" Biol Psychiatry (2014) 10.1016/j.biopsych.2013.07.031

[12]

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

A. Liberati, D. G Altman, J. Tetzlaff et al.

BMJ 2009 10.1136/bmj.b2700

[13]

Clinical diagnosis of Alzheimer's disease

Guy McKhann, David Drachman, Marshall Folstein et al.

Neurology 1984 10.1212/wnl.34.7.939

[14]

Friede "Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice" Anat Rec (1970) 10.1002/ar.1091670402

[15]

Schmechel "Brain endolases as specific markers of neuronal and glial cells" Science (1978) 10.1126/science.339349

[16]

Laterza "Identification of novel brain biomarkers" Clin Chem (2006) 10.1373/clinchem.2006.070912

[17]

Ockner "A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues" Science (1972) 10.1126/science.177.4043.56

[18]

Bonneh-Barkay "YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor" Am J Pathol (2008) 10.2353/ajpath.2008.080045

[19]

Horbinski "YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas" Int J Clin Exp Pathol (2010)

[20]

Ishizuka "Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease" Psychiatry Clin Neurosci (1997) 10.1111/j.1440-1819.1997.tb02375.x

[21]

Brenner "Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease" Nat Genet (2001) 10.1038/83679

[22]

Olsson "Biomarker-based dissection of neurodegenerative diseases" Prog Neurobiol (2011) 10.1016/j.pneurobio.2011.04.006

[23]

Whiting "Development and validation of methods for assessing the quality of diagnostic accuracy studies" Health Technol Assess (2004) 10.3310/hta8250

[24]

Bossuyt "The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration" Ann Intern Med (2003) 10.7326/0003-4819-138-1-200301070-00012-w1

[25]

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

Beverley J Shea, Jeremy M Grimshaw, George A Wells et al.

BMC Medical Research Methodology 2007 10.1186/1471-2288-7-10

[26]

Mattsson "CSF biomarker variability in the Alzheimer's Association quality control program" Alzheimers Dement (2013) 10.1016/j.jalz.2013.01.010

[27]

(1998)

[28]

Friedrich "The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study" BMC Med Res Methodol (2008) 10.1186/1471-2288-8-32

[29]

Meta-analysis in clinical trials

Rebecca DerSimonian, Nan Laird

Controlled Clinical Trials 1986 10.1016/0197-2456(86)90046-2

[30]

Jensen "Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression" Ann Neurol (1999) 10.1002/1531-8249(199904)45:4<504::aid-ana12>3.0.co;2-9

[31]

Osorio "Soluble amyloid-beta levels and late-life depression" Curr Pharm Des (2014) 10.2174/13816128113199990502

[32]

Buchhave "Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia" Arch Gen Psychiatry (2012) 10.1001/archgenpsychiatry.2011.155

[33]

Bateman "Clinical and biomarker changes in dominantly inherited Alzheimer's disease" N Engl J Med (2012) 10.1056/nejmoa1202753

[34]

Jansen "Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis" JAMA (2015) 10.1001/jama.2015.4668

Cited By

1,776

Ira Driscoll, Rachael E. Wilson · 2026

Journal of Alzheimer’s Disease

Tau‐targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy

Christopher M. Brown, Jeanne K. Brooks · 2025

Brain Pathology

Blood biomarkers for clinical applications in Alzheimer's disease: A narrative review

Hejie Li, Zhe Wang · 2025

NeuroMarkers

Cerebrospinal fluid HSP90AA1, HSPA4, and STUB1/CHIP levels in Alzheimer's disease, mild cognitive impairment, and frontotemporal dementia

Pelin Sordu, Merve Alaylıoğlu · 2025

Journal of Alzheimer’s Disease

Personalized modeling of Alzheimer's disease progression estimates neurodegeneration severity from EEG recordings

Lorenzo Gaetano Amato, Alberto Arturo Vergani · 2024

Alzheimer's & Dementia: Diagnos...

Photobiomodulation in experimental models of Alzheimer’s disease: state-of-the-art and translational perspectives

Zhihai Huang, Michael R. Hamblin · 2024

Alzheimer's Research & Therapy

Recent advances in electrochemical biosensors for the detection of Aβ42, a biomarker for Alzheimer disease diagnosis

Minling Ding, Shichao Ding · 2023

TrAC Trends in Analytical Chemistry

Tau-targeting therapies for Alzheimer disease: current status and future directions

Erin E. Congdon, Changyi Ji · 2023

Nature Reviews Neurology

CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease

Masanori Kurihara, Hiroki Komatsu · 2023

Neurology

Slowing gait speed precedes cognitive decline by several years

Tobias Skillbäck, Kaj Blennow · 2022

Alzheimer's & Dementia

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

Charlotte E Teunissen, Inge M W Verberk · 2022

The Lancet Neurology

2022 Alzheimer's disease facts and figures

· 2022

Alzheimer's & Dementia

Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease

Neus Barranco, Virginia Plá · 2021

Translational Neurodegeneration

Blood‐based biomarkers for Alzheimer's disease

Antoine Leuzy, Niklas Mattsson‐Carlgren · 2021

EMBO Molecular Medicine

Alzheimer's disease associated with Down syndrome: a genetic form of dementia

Juan Fortea, Shahid H Zaman · 2021

The Lancet Neurology

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

C. Delaby, D. Alcolea · 2020

Scientific Reports

Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker Panel for the Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment: A Pilot Study

Ali Yilmaz, Zafer Ugur · 2020

Metabolites

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

Niklas Mattsson-Carlgren, Sebastian Palmqvist · 2020

Nature Communications

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Fangda Leng, Paul Edison · 2020

Nature Reviews Neurology

Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults

Ane-Victoria Idland, Roser Sala-Llonch · 2020

Neurobiology of Aging

Metrics

1,776

Citations

34

References

Details

Published: Jun 01, 2016
Vol/Issue: 15(7)
Pages: 673-684
License: View

Authors

Alzforum, Cambridge, MA, USA

Cite This Article

Bob Olsson, Ronald Lautner, Ulf Andreasson, et al. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. The Lancet Neurology, 15(7), 673-684. https://doi.org/10.1016/s1474-4422(16)00070-3

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

You May Also Like